Evgen Pharma Share Discussion Threads

[nobbygnome] 02/9/2021 20:50

Good to see the orphan drug designation and the speed it was granted. I don't think I have ever seen the FDA act so quickly!

[moneymunch] 02/9/2021 20:37

More news from the rest of the pipeline at anytime, and let's hope progress has been made by the CBO on the "focus on potential partnering activities for SFX-01." Gla ;-)

[aaron87ward] 02/9/2021 20:28

What sort of price action do people expect tomorow? I was surprised it pulled back as far as it did into the close. The news is seriously good!!

[the skipper] 02/9/2021 19:57

Ditto to that. The day traders had their fun today but the bigger gains will go to those who follow the big money which is flooding in here.

[lovewinshatelosses] 02/9/2021 18:05

Well, I am surprised we did not finish closer to 8p in truth, but good to see Kight continuing to build an increasingly respectable position here. Even though I am a little overweight here already, if we revisit 6's in the days ahead, I am going to buy more myself, because I anticipate more material news in the medium term, if not sooner. GLA.

[markth126] 02/9/2021 16:17

But cant sell 250000 for 7p no problem. Someone is gathering still

[markth126] 02/9/2021 16:15

cant buy any more than £500 worth - been trying since it started dropping from 7.4

[jusjusjus] 02/9/2021 16:02

herb - went up today!

day traders leaving having realised there's no money to be made today
Kight may scoop some more up
when the time is right new long term holders will underpin a steady, sustained rise, we don't need these spikes yet!

[amaretto1] 02/9/2021 16:02

If it ends flat ..... that's a serious negative imo !!!

[herb clark] 02/9/2021 15:48

Will this ever go up?

[lovewinshatelosses] 02/9/2021 14:52

I think we will start to get some new investors here from next week, as today's news gets digested in the days (and the weekend) ahead. That said, over 17m traded so far cannot just be existing II's and PI's, including Kight's 1m, so maybe traders?
Either way, I am struggling to see the appeal of selling any stock right now, even allowing for a retrace at some point. Even if I had a 5p average and was only in for a quick trade, I would be looking for at least 10p to that end, but each to their own of course.

[on target] 02/9/2021 14:35

Looks like Kight's going higher - added another 1M today.

[demark] 02/9/2021 13:08

not sure whether the following
current holders are adding or
new buyers are in the market,
or just day traders milking
the rise!

time will tell!!

MAJOR SHAREHOLDINGS
Major shareholder Number of shares Percentage holding
J. R. Kight 24,000,000 8.7%
AXA Framlington 23,848,884 8.7%
Octopus Investments 21,875,000 8.0%
SPARK Impact 16,186,446 5.9%
Seneca Investment Managers 14,932,071 5.4%
Chelverton Asset Management 12,500,000 4.5%
RAB Capital 8,750,000 3.2%
Newlands Capital 8,314,815 3.0%

[moneymunch] 02/9/2021 12:51

1st Tee beckons...Gla...In and UPand straight down the middle!!!:')

[trad3m3] 02/9/2021 12:50

I think 2011 gap fill 60.00 :)

[amrishbhim] 02/9/2021 11:48

Should hit its high for the year, excellent approval and USA

[moneymunch] 02/9/2021 11:35

On the US radar!!! ;-)


02 September 2021

Evgen Pharma plc

("Evgen" or the "Company")

Glioma Orphan Drug designation for SFX-01 granted by FDA

Evgen Pharma plc (AIM: EVG), a clinical stage drug development company developing sulforaphane based medicines for the treatment of multiple diseases, announces the grant of an Orphan Drug Designation ("OD") by the US Food and Drug Administration ("FDA") for use of SFX-01 to treat malignant glioma.

The Company, announced submission of an Orphan Drug application to the FDA on 13 July 2021. OD is usually granted when there are fewer than 200,000 patients with a given disease in the United States and there is a scientific rationale for potential use of the product in that condition. As well as recognising the relative rareness of a disease, OD confers intellectual property cover to an investigational drug in the form of data protection at the time of approval of a new drug application, which is additional to any patent cover in force. Tax credits are also possible on eventual US sales of an approved orphan drug.

Dr Huw Jones, CEO of Evgen, commented: "We are delighted that our team and advisors have successfully gained Orphan Drug designation for SFX-01 in the USA in a very short period of time. This is part of a wider strategy to access the US market and positions us well for further investigations of our lead asset in this devastating brain cancer as we continue to optimize SFX-01 for clinical trials and eventually partnering."

[lovewinshatelosses] 02/9/2021 11:35

Demark: I cannot speak for others, but I have held/hold other small caps that offer less potential (IMO) than EVGEN that sailed above the 100m m/cap territory in reasonably short order. I certainly never invested here for small potatoes and feel more confident now than I have done for quite some time.
But I am often a bellwether to do the opposite of copy, and furthermore, I have now drifted into ramper territory :)
Anyway, I am really looking forward to the next few months here; hopefully a fair bit of newsflow and interviews, which I always say small caps never seem to do enough of, for my liking. GLA.

[on target] 02/9/2021 11:09

Yes you would think so, although obviously with time zone differences that may not always be possible.

[demark] 02/9/2021 11:07

On Target,

if FDA refers an entity's
name in their website,
then due to price sensitivity
FDA ought to inform the entity
concerned either before or at
the same time!

[herb clark] 02/9/2021 10:58

What will it do to price?

[on target] 02/9/2021 10:57

Wonder if Evgen have to wait for a formal communication from the FDA before they can issue an RNS or something? If so we may be waiting 1-4 hrs depending on what timezone the relevant office is in?

[david gruen] 02/9/2021 10:12

Without doubt! (and more) Start with the website to feel the potential on offer here.